Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome

This lecture was part of a CME accredited symposium; SGLT2 inhibition, diabetes and CVD: Where does this fit in CV risk management? held at ESC 2016 in Rome

Development of anti-diabetic medication over the past years 00:14
Anti-diabetic medications target different mechanisms 01:40
Working mechanism of SGLT-2 inhibitors 04:10
Effectivity of SGLT-2 inhibitors 06:41
CV effect of SGLT-2 inhibitors 10:30
Effect of SGLT-2 inhibitors on renal function 15:11
ADA/EASD position statement for treatment of diabetic patients 17:24

Educational information

Educational objectives of this symposium were to:

Summarise the epidemiology and pathophysiology of patients at increased cardiovascular risk and diabetes
Identify key components of renal glucose handling and the contribution of the kidney to glucose homeostasis
Describe the effect of multiple interventions that currently are deployed for T2D on cardiovascular safety and the currently unmet need on impacting cardiovascular outcomes-
Explain, based on scientific evidence, the effects that SGLT2 inhibiting agents may have on cardiometabolic markers, including lipids, weight gain, risk of hypoglycemia, HbA1c, glucose levels, related markers and cardiovascular outcomes
Discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multi-risk patients

CME accreditation

This symposium was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Faculty & Disclosures

Prof Silvio Inzucchi MD, is Professor of Medicine at the Yale School of Medicine in New Haven, Connecticut, US, where he serves as Clinical Chief of the Section of Endocrinology and Medical Director of the Yale Diabetes Center

Funding

Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

Also view lecture: Challenging cardiovascular risk in diabetes: ready for a new approach? by prof John Deanfield, MD, University College London, United Kingdom Also view lecture: Heart Failure & Diabetes: SGLT2 inhibition a paradigm shift? by prof John McMurray, MD University of Glasgow United Kingdom